… benefits and adverse effects of sacubitril/valsartan in heart failure, with a focus on important
… comparing sacubitril/valsartan versus a reference drug, in heart failure patients with reduced (…

… for patients with chronic heart failure (CHF)… valsartan (LCZ696) has been recently approved
for CHF patients as it reduces cardiovascular (CV) deaths and hospitalization for heart failure …

… in the treatment of patients with chronic heart failure (HF) with reduced ejection fraction (HFrEF).1
In the PARADIGM-HF trial, sacubitril/valsartan was found to be superior to the …

… (PRA) in chronic heart failure (HF) … chronic HF treated with ACEi and beta-blockers.
METHODS AND RESULTS: PRA was measured in 4,291 patients from the Valsartan Heart Failure …

… chronic heart failure (HF) remain at high risk for HF progression and death. Sacubitril/valsartan …
II (Ang-II) receptor blocker (valsartan). NEP is an endopeptidase that metabolizes …

… the rate of heart failure hospitalization. The benefit of sacubitril/valsartan over enalapril was
… For example, the sacubitril/valsartan versus enalapril hazard ratio for the primary endpoint …

… with sacubitril/valsartan reduced the primary outcome of cardiovascular (CV) death and
heart failure (HF) hospitalization compared with enalapril in patients with chronic HF and …

… Sixty consecutive patients with chronic heart failure and NYHA class II-III were followed up
for 12 months after therapy with sacubitril/valsartan. Left and (RV) function was assessed at …

… of sacubitril/valsartan in patients with both heart failure and CKD, … heart failure and CKD
were included in this meta-analysis. Sacubitril/valsartan was compared with irbesartan, valsartan …

Aims Sleep‐disordered breathing (SDB) is a highly prevalent co‐morbidity in patients with
chronic heart failure (CHF) and can play a detrimental role in the pathophysiology course of …